Tikva Allocell to Showcase Innovations at Asian Pharma Conference in Singapore

Tikva Allocell, an innovative biotechnology firm based in Singapore, has announced its participation in the upcoming Asian Pharma and Biotech Project, Program and Portfolio Management Conference, scheduled for August 5-6, 2025. The company's Founder and CEO, Dr. Ivan Horak, will be a key speaker on the panel that addresses the evolving landscape of the pharmaceutical and biotech industries in Asia.

This event offers a platform where industry leaders will discuss the critical factors influencing drug development in the region, highlighting the need for innovation, investment, and strategic growth. Dr. Horak expressed his enthusiasm about the opportunity to discuss how these elements are shaping the future landscape of drug development, particularly for advanced therapies for cancer.

Tikva Allocell is known for its pioneering work in developing off-the-shelf CAR-T cell therapies specifically designed to combat solid tumors. The company's CAR-T products utilize an allogeneic Epstein-Barr Virus Specific T cell (ALLO EBVST) platform. This innovative approach is crucial in enhancing T cell persistence while minimizing potential complications such as graft-versus-host disease (GvHD) without resorting to genetic modifications.

The upcoming panel discussion is titled "The Evolving Pharma and Biotech Landscape in Asia: Accelerating Drug Development Through Innovation, Investment, and Strategic Growth." Here, experts will delve into the current state of drug development in Asia and discuss opportunities and challenges confronting clinical trials, research and development (R&D), and commercialization efforts. They will also explore how incubators, governmental agencies, and venture funding are instrumental in fostering early-stage innovations and expediting development processes.

In addition, conversations will cover significant regulatory changes, the impact of artificial intelligence, and the emergence of new technologies that are fundamentally transforming both clinical development and portfolio management in the region. The discussions aim to provide insights into the dynamics of modern-day pharmaceutical development and the integral role of collaboration among various stakeholders.

During the conference, Dr. Horak will also have the chance to engage in one-on-one interactions with investors and potential strategic partners. This is part of Tikva's strategy to showcase its clinical development roadmap, recent milestones, and future goals. The company's leading product, TAVST01, is specifically aimed at targeting B7-H3 positive solid tumors, which include various cancer types such as lung, breast, prostate, and pancreatic cancers. Preclinical studies on TAVST01 have demonstrated promising results, targeting both tumor cells and the immunosuppressive micro-environment typically found in solid tumors, enabled by its potential lymphodepletion-free safety profile that allows for multiple dosing or combination therapies.

The conference will take place at the One Farrer Hotel in Singapore, beginning at 9:00 AM SGT on August 5, 2025. Tikva Allocell is positioned to play a key role in the future of drug development, especially in the landscape of CAR-T therapies, and this event underscores their commitment to advancing innovative solutions in oncology treatments.

For more information on Tikva Allocell and its groundbreaking research, visit their official website at www.tikvaallocell.com. Denmark-based Tiberend Strategic Advisors, Inc. handles investor relations, while media inquiries can also be directed to their team.

The Asian Pharma and Biotech Conference marks a pivotal moment for Tikva as it continues to drive innovation in the biotech sector and contribute to breakthroughs that will benefit patients worldwide.